The CDC and FDA Recommends Pausing the Johnson & Johnson Vaccine Due to Reported Blood Clotting
Photo by Macau Photo Agency via Unsplash
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) announced a recommended pause on administering the Johnson & Johnson vaccine due to reports of potential blood clotting.
“Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution,” the FDA tweeted April 13.
As of yesterday, 6.8 million doses of the Johnson & Johnson vaccine have been administered.
The CDC and FDA are reviewing the data from six reported cases of blood clotting after receiving the new vaccine.
The CDC released an official statement on April 12, explaining the severity of the recommendation.
“In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia),” according to the statement.
“All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination.”
“Treatment of this specific type of blood clot is different from the treatment that might typically be administered.”
The CDC says authorities are taking precautions in researching the Johnson & Johnson vaccine.
“Right now, these adverse events appear to be extremely rare,” the statement said. “COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously.”
“People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.”
With this new recommendation to pause the vaccine’s release, some have said that it may delay the fight against COVID-19.
So far, there have been zero blood clot cases regarding the Pfizer and Moderna vaccines.